§ Federal grant opportunity · PAR-25-357
NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)
National Institutes of Health is accepting applications for NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed). The deadline is October 16, 2027 and the published award range is Award amount not published.
Key facts
- Funder
- National Institutes of Health
- Application deadline
- October 16, 2027
- Award range
- Award amount not published
- Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- Geography
- United States
- Focus areas
- Health
- Opportunity number
- PAR-25-357
Program overview
The goal of this funding opportunity announcement (FOA) is to fund meritorious vision-related research projects that involve secondary data analyses using existing database resources. The development of statistical methodology necessary for improving methods to analyze vision health data using existing vision data may also be proposed.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from National Institutes of Health.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before October 16, 2027, allowing time for registration and validation.
Related grant opportunities
- NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)
- Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
- Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
- Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
- Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.